Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 463.56% and ...

Eli Lilly stock undercut its 50-day line on Jan. 14 after cutting its fourth-quarter and 2024 outlook. Is LLY stock a sell ...

AbbVie's CEO hinted his company may be less willing to invest in psychiatry after a costly setback, while Lilly explained ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

The weight-loss succession race is heating up. Here's how biopharma execs talked up those efforts at JPM this week.

A Bucks County woman is speaking out after her insurance company decided to no longer cover weight loss drugs.

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

“We stumbled into one room that was set up, sort of like a lab,” said Johnie Carter ... Counterfeit versions of Wegovy or Zepbound are different from compounded weight loss drugs.

Pharmacy professor Nicole Albanese discusses the science behind drugs like Ozempic and Wegovy, their potential to treat other ...

Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...

Several years ago, Noah Oppenheim, then the president of NBC News, was talking shop with New York Times reporter Michael ...

An international and widely supported group of experts is pushing doctors to avoid the exclusive use of BMI to decide whether ...